Lexeo Therapeutics Inc
For the period ended Dec 31, 2023. Filed Apr 26, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Dec 31, 2023 · Filed Apr 26, 2024
Use the contents to explore the available documents and sections.
Contents
Board Composition
Our board of directors currently consists of seven members. Bernard Davitian is not standing for re-election at the Annual Meeting. Accordingly, following the Annual Meeting and assuming the re-election of Ms. Agger at the Annual Meeting, one Class I Director vacancy will exist. The Board intends to fill this vacancy as soon as it finds a suitable candidate and is actively engaged in a process to do so. Our directors are divided into three classes serving staggered three-year terms. Upon expiration of the term of a class of directors, directors in that class will be eligible to be elected for a new three-year term at the annual meeting of stockholders in the year in which their term expires. As a result of this classification of directors, it generally takes at least two annual meetings of stockholders for stockholders to effect a change in a majority of the members of our board of directors.
The principal occupations and certain other information about the nominees and the additional members of our board of directors (including the skills and qualifications that led to the conclusion that they should serve as directors) are set forth below.
| Name | Class | Age | Position(s) | Director Since | CurrentTermExpires | Expirationof Term for WhichNominated |
|---|---|---|---|---|---|---|
| Nominee for Director | ||||||
| Mette Kirstine Agger(1)(3) | I | 59 | Class I Director | 2020 | 2024 | 2027 |
| Continuing Directors | ||||||
| Steven Altschuler, M.D.(2)(4) | II | 70 | Chairman of the Board of Directors and Class II Director | 2021 | 2025 | - |
| Reinaldo Diaz (1)(2)(3) | II | 70 | Class II Director | 2022 | 2025 | - |
| R. Nolan Townsend | III | 44 | Chief Executive Officer and Class III Director | 2020 | 2026 | - |
| Brenda Cooperstone, M.D.(3)(4) | III | 59 | Class III Director | 2023 | 2026 | - |
| Paula HJ Cholmondeley(1)(2) | III | 77 | Class III Director | 2021 | 2026 | - |
| Bernard Davitian* | I | 63 | Class I Director | 2020 | 2024 | |
- Bernard Davitian is a director as of April 26, 2024 but has decided not to stand for re-election; accordingly, his term will expire effective as of the commencement of the Annual Meeting.
(1)
Member of the audit committee
(2)
Member of the compensation committee
(3)
Member of the nominating and corporate governance committee
(4)
Member of the science and technology committee
-8-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.